Synairgen Share Discussion Threads

[nobbygnome] 02/5/2020 11:22

Thanks. So just a rumour....

I maintain no-one will have an overall picture of the results. Remember the trial is taking place in multiple centres and as you say it is blinded so no-one knows who is getting drug. The only caveat to that is if there is a really dramatic rapid effect, which I somehow doubt because they would have seen that in the COPD study too. Also remember this is a new virus so no-one really knows the standard course of the disease so comparisons are difficult.

[crookie3634] 02/5/2020 11:12

Nobby can’t confirm its anymore than rumour from a poster on LSE who knows Richard. But when you look at the different pieces of information I could see there being something to it, they will need a partner to scale this up, they raised funds for this purpose why wouldn’t they be putting in place support behind the scenes to help with scaling up? What did you think to the early data element? Looks to me like they have seen something positive without unblinding the trial early signs but still risk of not knowing the end result.

[nobbygnome] 02/5/2020 10:50

Could someone tell me where the Evercore rumour came from? Is there any credence to this rumour?

Looking at their functions, the only one which might be relevant is the M&A part....

[nobbygnome] 02/5/2020 10:46

For those of you who love an RNS there is another guaranteed one in the not too distant future. Richard has confirmed to me they will announce when the at home treatment study starts!

[crookie3634] 02/5/2020 10:10

Strengthened balance sheet for potential partnering GBP3m
discussions with regards to the COVID-19, future
pandemic preparedness, and the COPD opportunity,
working capital and fees

Just saying .....

[crookie3634] 02/5/2020 10:08

Evercore’s Strategic Advisory business provides differentiated strategic and tactical advice as well as unparalleled execution to financial sponsors and both public and private companies across a broad range of industry sectors and geographies. We help our clients identify and pursue strategic priorities, devise strategies to enhance shareholder value, and develop new ideas and deeper perspective to achieve their goals. We advise boards and management teams on how to successfully develop relationships with and communicate their strategies and M&A transactions to their shareholders. Our success begins and ends with an unrelenting commitment to delivering world-class client service.

Mergers & Acquisitions
In advising companies on an acquisition, merger, or sale, we evaluate potential targets, provide valuation analyses, and evaluate and propose financial and strategic alternatives. We provide boards and management teams with independent judgment and deep expertise as they navigate their most important transactions and strategic decisions. We also advise as to the timing, structure, financing, and pricing of a proposed transaction as well as assist in negotiating and closing the deal.

Previously....

Evercore Partners International LLP, which is authorised and regulated in the United Kingdom by the Financial Conduct Authority, is acting as financial adviser exclusively for AstraZeneca

Interesting link, rumours but just maybe....

[best1467] 02/5/2020 08:46

Investment advising bank EVR

[vitec] 02/5/2020 00:43

I think it has passed 70p on 3 separate occasions and not managed to hold. It needs the trial to be positive and then I do not think you will even see 70p as the share price will be much higher from the start.

[svenice7] 02/5/2020 00:25

If this passes 70p it will fly to 2 pound.

[crookie3634] 02/5/2020 00:06

Looking to close out the Asthma Placebo trial by adapting the conditions for remaining 11 patients. Results Summer 2020 regardless of Covid activity.

This trial is also double blinded and placebo method. Yet note the paragraph reading Early Data, yet to be unblinded but they used Sputum Biomarkers to assess activity in the lung. Could this be the same way they have assessed Early Data from the current trial and hence pushed on to the extension, I think it could be, that’s why they are positive it works.

Look at the next bit use of proceeds, 4mill already assigned to manufacture the drug, I wonder how much of the 7 mill for the current trial is drug cost and how much is everything else? How much would 4 mill get? Then 3mill on top of current cash balance of 2.45 mill for future partnering discussions? Rumours of RM having meetings with Evercore I wonder what they do?? Or why he would need that meeting? I think there is so much to come here and believe a lot is going on in the background. They know they can’t go it alone so who are they going to sign up with? Deals for Covid and COPD IMO. The results from the previous COPD studies look perfect for Covid as the best results were shown with the people who would suffer most hence why they are being precise with recruitment. This has a high chance of being successful and they know it IMO. Plenty of news to come.

[crookie3634] 01/5/2020 23:49

Synairgen is now close to completing a Phase II study in COPD patients with confirmed respiratory viral infections and pre-existing significant impairment of lung function. With 109 out of a target 120 participants already dosed, this trial has been paused to minimise the chance of vulnerable patients being exposed to further infection risk and to minimise distraction for respiratory staff in the UK hospitals and GP sites conducting the trial, who will be at the forefront in dealing with patients suffering from COVID-19. The Company is currently exploring ways to adapt the trial to enable patients in the pre-treatment pool to be dosed if they become infected with SARS-CoV-2.
Early data from this double-blind, placebo-controlled trial have demonstrated that the antiviral responses in the lung (assessed using sputum biomarkers) are similar to those observed in the asthma trial, where we saw clinical benefit in lung function.
Use of proceeds


COVID-19 clinical trial activity GBP7m
Manufacture of SNG001 drug product and other supply GBP4m
chain considerations
Strengthened balance sheet for potential partnering GBP3m
discussions with regards to the COVID-19, future
pandemic preparedness, and the COPD opportunity,
working capital and fees

3. Current Trading and Future Prospects
Synairgen has recruited 109 of the 120 patients required for its IFN-beta trial in COPD, with data expected in Summer 2020. The opportunity now afforded to the Company with regards to COVID-19 is significant and the trial of SNG001 is expected to commence imminently. As at 31 December 2019, the Company had cash of approximately GBP2.45m (unaudited).

[crookie3634] 01/5/2020 23:25

The study, therefore, suggests that IFN-β treatment may be most appropriate for the more difficult to control people with asthma in whom the underlying disease process is likely to be more severe, thus requiring more intensive treatment, and in whom the risks of exacerbations, health impact, and treatment costs are greatest (24).

Looks well tuned to Covid19??

Thus, nebulized IFN-β treatment is the first therapy acting on the causal viral pathway that seems able to prevent worsening of asthma symptoms if administered shortly after patients become aware of a cold developing.

Not surprising they want to get it into Covid19 sufferers early.

IFN-β was selected for clinical development based on abundant evidence of its safety in multiple sclerosis

Can’t see safety being an issue. All looks really positive and I am hoping it displays the above against Covid.

[judijudi] 01/5/2020 22:59

Still got the insti selling

[torreskid] 01/5/2020 22:02

is Remdesivir approved for other indications? then EUA approval is str8 forward in these times

[rosco230667] 01/5/2020 21:51

Does anybody have an explanation of all these trades with much higher prices than the share traded at today and the diff erraticTimes

[crookie3634] 01/5/2020 21:29

Nobby bet you were chuffed with the home trial addition. 2 more weeks of recruitment into Hospital trial, start analysing last week of May results by mid June I reckon.

[nobbygnome] 01/5/2020 21:21

It is disgraceful that remdesivor has been approved. There is no way the data is good enough for approval and it sounds like it will be used in a very limited number of patients. It bodes well for rapid approval of SNG001 if they get good results from a placebo controlled trial.....

[crookie3634] 01/5/2020 21:18

Something happening behind the scenes Peachy. Look at the graph the train is being held in the station! Being sold out sensibly into riding volume and buying demand. But someone is buying big, 16-18 mill Griffiths shares gone! 4 mill Lansdowne placing shares gone! PI have not absorbed that surely? Changing hands IMO.

[a.fewbob] 01/5/2020 21:02

Does Remdesivir actually work?

I am getting very mixed messages from the press!!

[peachie 74] 01/5/2020 20:54

Yep Makendon...ridiculous amounts of big trades recorded late. Something has to be happening behind the scenes. Or is it just AIM MMs who seem to do what the f+++ they want ?

[euclid5] 01/5/2020 20:53

President Trump tells reporters that Gilead has gotten an emergency use authorization for its coronavirus drug remdesivir, Bloomberg News reports.

[adman50] 01/5/2020 20:01

Another week down only a few more to go. Stay safe everyone and have a great weekend. The wife has got me repainting the living room ☠

[pdt] 01/5/2020 17:55

Our partner Pharmaxis gave an update yesterday on LOXL2 inhibitor in which we have a stake.

 LOXL2 partnering
While slowed by the diversion of attention of potential partners in the last quarter there has certainly been no reduction in the number interested parties. The data generated by the small phase 1 study completed this quarter has been helpful in maintaining momentum and underlined the consistent quality of our science. We expect the further development of this program to be partner funded.

[makendon] 01/5/2020 17:49

Anyone see the after hours trading???? Huge amount of transactions under the ? Column

Actually there were ......3,544,878 - sh*t bags 🤷🏻